Key terms
About LGVN
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LGVN news
Apr 18
4:43pm ET
Longeveron Bolsters Market Position with Strategic Financing
Apr 17
8:12am ET
Longeveron announces exercise of warrants for $6.2M gross proceeds
Apr 08
2:25pm ET
Longeveron 2.234M share Secondary priced at $2.35
Mar 26
7:50pm ET
Longeveron Inc trading halted, news pending
Mar 19
5:16pm ET
Longeveron files to sell Class A common stock, warrants, no amount given
Mar 19
4:12pm ET
Longeveron Announces Reverse Stock Split Approval
Mar 19
4:06pm ET
Longeveron announces 1-for-10 reverse split of common stock
Mar 01
3:25pm ET
Longeveron (LGVN) Receives a Buy from Maxim Group
Feb 22
4:15pm ET
Longeveron Stockholders Approve Reverse Split and Charter Amendment
Jan 29
4:07pm ET
Longeveron files to sell 1.45M shares of Class A common stock for holders
No recent press releases are available for LGVN
LGVN Financials
Key terms
Ad Feedback
LGVN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LGVN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
